The feasibility and safety of outpatient management of acute promyelocytic leukemia (APL) during the aplastic phase after intensive consolidation chemotherapy, the incidence and types of complications requiring readmission to hospital, and the number of hospital days spared by this policy have been prospectively evaluated. After chemotherapy administration, patients were evaluated on an ambulatory basis. In the event of any complication they referred to the Emergency Unit (EU) of our Department dedicated to outpatients with hematologic diseases. Forty patients with APL observed over a 4 year period were eligible for intensive chemotherapy. After the achievement of complete remission they received a total of 104 consolidation courses and in 98 instances they were followed on an ambulatory basis. There were 41 cases (42%) of rehospitalization for fever (40 cases) or severe anemia (one case). Only one patient died due to a brain hemorrhage. Streptococcus viridans was the organism most frequently isolated from blood. Empiric once-a-day antibacterial therapy with ceftriaxone and amikacin was effective in 87% of the cases and made possible early discharge in 28% of the cases to continue the antibiotic therapy on an outpatient setting. Patients were managed out of the hospital for 76% of the post-consolidation neutropenia period. Thanks to the availability of an EU specifically dedicated to outpatients with hematologic diseases, out-hospital management of APL patients after consolidation therapy appeared to be safe, well accepted, potentially cost-saving, and contributed to saving the risk of developing severe nosocomial infections.
Introduction
Disease-free survival (DFS) of acute myeloid leukemia (AML) patients achieving complete remission (CR) after induction phase has been prolonged, in the recent years, by therapeutic approaches based on intensive consolidation treatments. 1, 2 Among AML a particular subtype is represented by acute promyelocytic leukemia (APL), where more than 90% of patients achieve CR with specific induction treatment including alltrans retinoid acid (ATRA) and anthracycline-based chemotherapy; however, in order to also obtain molecular remission and prevent hematologic relapse, intensive consolidation chemotherapy has been shown to be necessary. [3] [4] [5] To improve DFS, it is also necessary for an accurate management of febrile and hemorrhagic episodes that frequently complicate bone marrow aplasia following consolidation chemotherapy, implying a prolonged hospitalization of patients.
The increasing attention to the quality of life and to health care costs, in addition to the higher risk of severe multiresistant nosocomial infections, has induced modification of inpatient management to an outpatient setting.
Correspondence: C Girmenia; Fax: 06 44241984 Received 2 December 1998; accepted 30 December 1998 Such an approach, recently presented in preliminary reports, 6, 7 is currently under investigation at the Emergency Unit (EU) of our Department in several categories of patients with hematologic malignancies. This EU is dedicated to outpatients with hematologic diseases requiring immediate clinical evaluation, therapeutic intervention and hospitalization for all kinds of emergencies, including those following intensive chemotherapy.
The aims of this prospective study were: (1) to evaluate feasibility and safety of outpatient management of APL patients observed at our Center over a 4 year period during consolidation phase; (2) to determine the incidence and types of complication which require readmission to hospital, in addition to clinical and microbiologic data of infective causes. Hence, this information was used to evaluate the number of hospital days spared by this policy in patients with APL eligible for a post-remissional intensive treatment.
Patients and methods
All patients aged у20 years with a new diagnosis of APL followed at our Institution between July 1994 and August 1998 and eligible for intensive chemotherapy with the AIDA-GIMEMA protocol entered this study. 5 The treatment schedule of the protocol is summarized in Table 1 .
Patients were treated in the ordinary wards for the length of the induction phase until achievement of hematologic CR and normalization of peripheral blood counts. After the achievement of hematologic CR, patients received three consolidation polychemotherapy courses. Each consolidation course was administered at recovery from the previous course when polymorphonuclear cells (PMN) and platelets (PLTS) count were Ͼ1500/mm 3 and Ͼ100 000/mm 3 , respectively. The first two courses and the third course were administered on an inpatient and outpatient basis, respectively.
Usually, patients treated as inpatients were discharged at the end of consolidation chemotherapy regardless of their absolute PMN or PLTS count, provided they were in good clinical condition, without fever and/or bleeding and they were not receiving intravenous therapy.
Condition for outpatient management in this post-consolidation phase was a limited distance between patient residence and hospital location (Ͻ2 h, by car). Patients living too far from the hospital were allocated to a nearby patient residence.
Only a few patients with difficult peripheral vein access had an indwelling central venous catheter (Groshong catheter). All patients received antibacterial prophylaxis with oral ciprofloxacin (500 mg twice a day) and anti-hemorragic prophylaxis with oral tranexamic acid (100 mg/kg/day) and prednisone (25 mg/day). Antibacterial and antihemorragic prophylaxis were administered until increase of PMN to 1 × 10 9 /l and of PLTS to 50 × 10 9 /l, respectively. Patients were standardly evaluated on an ambulatory basis twice weekly; packed red blood cells and PLTS concentrates were administered as hemoglobin value and PLTS count were Ͻ8 g/dl and Ͻ10 × 10 9 /l, respectively. Patients were instructed to check themselves for vital parameters including oral temperature daily and to return immediately to our EU in case of fever (body temperature Ͼ38°C) and/or other signs of infection, bleeding or any other complication. A 24 h telephone line was also provided for patients to communicate with the EU if there were any problems and/or to reconsider patient admission to the EU where a six-bed ward was available for the emergencies.
Upon arrival at the EU, a complete clinical and laboratory check was performed. In the event of fever or other signs of infection, blood cultures were obtained (at least three at intervals of 15 min) as well as cultures from any presumed site of infection, and chest radiograph was performed. Patients with bleeding and patients with fever and profound thrombocytopenia (Ͻ20 × 10 9 /l) received PLTS concentrates (1 unit/10 kg body weight/session).
Within 1 h from arrival at the EU, all patients with febrile neutropenia were admitted and empirically treated with a daily intravenous dose of ceftriaxone (2 g) plus amikacin (20 mg/kg). Empiric antibiotic therapy was adjusted on the basis of therapeutic response and of results of culture and sensitivity tests. Antibiotic treatment was continued until 4 consecutive days without fever had passed or until microbiological and/or clinical evidence of infection had disappeared. Patients free from fever early and in good clinical condition were usually discharged regardless of their absolute PMN and PLTS count and continued antibiotic therapy as outpatients. In the event of prolonged hospitalization, patients admitted and initially treated at the EU ward were transferred to the ordinary wards of the Center.
Results
Forty patients with APL were eligible for intensive chemotherapy during the study period. There were 15 males and 25 females. The mean age was 44 years (range 21-72). All patients achieved CR and received a total of 104 consolidation courses. In 98 instances, patients were discharged immediately after chemotherapy administration or received the treatment as outpatients according to the protocol schedule, and were then followed on an ambulatory basis during the phase of bone marrow aplasia. Our analysis refers to these cases. In six cases, early discharge was not possible due to development of an infection (four cases) or other (two cases) complications.
During the period from discharge to recovery from bone marrow aplasia patients were seen at the ambulatory a mean of three times (range 0-4) and received a mean of two packed red blood cell transfusions (range 0-4) and two platelet concentrate transfusions (range 0-3) at the day-hospital.
Among 98 consolidation courses followed by ambulatory management, there were 41 cases of rehospitalization (42%) for fever (40 cases) or severe anemia (one case). The phase of the cytotoxic therapy and the rate of rehospitalizations for these patients are detailed in Table 2 . A significantly lower incidence of complications requiring hospitalization was observed after the third course of consolidation as compared to the first two courses (P = 0.02, Fisher's exact test).
On patient admission, mean PMN count was 50/mm 3 (range 0-200/mm 3 ), mean PLTS count was 10 000/mm 3 (range 4000-30 000) and mean hemoglobin value was 8.5 g/dl (range 5.5-10.5). On admission to the EU, in 36 instances the patients were in good clinical condition. Three patients presenting with septic shock and one patient with a symptomatic anemia (Hb 5.5 g/dl) rapidly recovered with treatment. Finally, a 61-year-old patient treated with the first consolidation course attended at the EU because of fever but 1 h after admission developed a fatal brain hemorrage.
Of the 40 febrile episodes 22 (55%) were of unknown origin. An infection was clinically documented in two cases (5%) (pneumonia and probable hepatosplenic candidiasis, one case each) and microbiologically documented in 16 cases (40%) ( Table 3) .
Streptococcus viridans was the organism most frequently isolated (seven cases). In the three patients with septic shock, septicemias due to E. coli, P. aeruginosa and P. aeruginosa plus Aeromonas spp. were documented, respectively. All microorganisms but Enterobacter cloacae, P. aeruginosa and coagulase-negative Staphylococcus (one patient each) were in vitro susceptible to both ceftriaxone and amikacin. The two patients with resistant P. aeruginosa and Enterobacter cloacae septicemia, respectively, had developed an infection with the same microorganisms during the induction treatment.
Thirty-four of 39 (87%) treated febrile episodes responded to initial empiric therapy with ceftriaxone plus amikacin while in five cases (13%) the fever disappeared after treatment modification (addition of teicoplanin in two cases, substitution of ceftriaxone with meropenem in two cases, addition of teicoplanin followed by amphotericin B in one case).
The mean time of readmission to the EU was 9.5 days (range 3-16) starting from the end of chemotherapy. Patients rehospitalization lasted a mean of 10 days (range 1-30, 418 cumulative days). Eleven of 39 (28.3%) patients treated for infective complications were discharged early after 3.5 mean days (range 2-6), regardless of their neutrophil and platelet count, to continue once-a-day antibiotic therapy with ceftriaxone plus amikacin as outpatients for a further 4 mean days (range 3-6). The other 28 patients received the complete antimicrobial therapy as inpatients. Eight of 41 (19.5%) patients admitted to the EU ward were eventually transferred to the ordinary ward of our Center for a cumulative 103 days, which represented 25% of the overall rehospitalization days.
Duration of post-consolidation neutropenia accounted for 1715 cumulative days (17.5 mean days; range 9-47). Our policy allowed management of these patients out of the hospital for 1297 cumulative days (13.2 mean days; range 5-29) which represents 76% of the post-consolidation neutropenia period.
Discussion
Increasing attention to the quality of life and to health care costs for cancer patients, has led to the development of strategies that move traditionally inpatient problems to the outpatient setting. Out-hospital management of neutropenic patients is also associated with a reduced exposure of the patient to antibiotic-resistant nosocomial infections. Therefore, ambulatory management of afebrile neutropenic and thrombocytopenic patients with leukemia is becoming a standard practice in several hematologic centers even though the risks and benefits of this approach have not yet been systematically studied. To our knowledge, only preliminary experiences based on such a policy have so far been published. 6, 7 In a prospective observational analysis, Gillis et al 6 evaluated 29 AML patients who received a total of 86 chemotherapy courses and were discharged early following 50 of these courses. Significantly more patients were discharged early after consolidation than after remission induction chemotherapy, as in only four (12%) of 33 induction treatments, patients were considered eligible for out-hospital management during bone marrow aplasia. In 47 (94%) instances, patients returned to the hospital, mainly because of fever, and only two deaths occurred. The authors concluded that selected discharge of patients during chemotherapy-induced neutropenia was generally safe and led to a saving of 16% of hospitalization in the total treatment of AML.
The present study, focused on patients with APL submitted to post-remissional consolidation chemotherapy, appears to confirm the above observation suggesting that out-hospital management can be a feasible option.
Discharge was possible following 94% of the consolidation courses. Rehospitalization was required in only 42% of the cases, and in the remaining 58% the patients were managed on an ambulatory basis during the whole period of induced aplasia. As expected, the third consolidation course, in which chemotherapy was also administered on an outpatient basis, appeared to be associated with a lower incidence of complications requiring hospitalization as compared to the first two courses (22.6 vs 50%).
Thanks to the availability of a brief-stay ward in the EU, only 25% of the rehospitalization time involved the ordinary wards of the hematologic Center.
In all but one course, rehospitalization was due to development of fever during severe neutropenia. In 40% of the febrile episodes the infection was microbiologically documented. Viridans streptococci were the most common causes of bacteremia accounting for 44% of the bloodstream isolates. In agreement with previous reports, 6 the most relevant data were the low incidence of multi-resistant microorganisms. In fact, in only two patients was a septicemia due to multi-resistant P. aeruginosa and E. cloacae, respectively, documented. However, in both cases the same microorganisms had been previously isolated while the patients were hospitalized for remission induction treatment. These data seem to confirm that out-hospital management of neutropenic patients is associated with a reduced incidence of infections with resistant hospital-acquired pathogens, even though such a possibility related to a previous hospitalization should be considered.
The association of ceftriaxone plus amikacin has been shown to be effective and suitable for empiric treatment of hospital-acquired infections in neutropenic cancer patients. [8] [9] [10] At our institution, this antibiotic regimen has been largely used in the last decade for the empiric treatment of febrile neutropenia in view of the broad spectrum of action and the oncea-day intravenous administration, which allows easy use and economic advantages. 9, 11 The possibility of intravenous antibiotic therapy administration once every 24 h is particularly useful in the setting of out-hospital management for several categories of patients. In a previous open pilot study at our Center, the association of ceftriaxone plus amikacin for the treatment of hematological patients with febrile neutropenia who required hospitalization permitted early discharge and continuation of treatment on an outpatient basis in over 50% of the cases, with 21% of hospitalization days. 12 In an our recent experience concerning the home management of patients with advanced hematologic malignancies, therapy with once-a-day ceftriaxone plus amikacin in febrile neutropenic subjects, was shown to be a suitable empiric treatment. 13 In the present study, this empiric treatment proved to be effective in 87% of the febrile episodes. The low incidence of septicemias due to multi-resistant gram-negative bacilli (thanks to the out-hospital management) and staphylococci (due to limited use of central venous catheters) seems to justify the high efficacy of this empiric antibacterial therapy in APL patients. The once-a-day antibiotic regimen allowed early discharge of the patients free from fever in 28.3% of the episodes to continue antibiotic therapy as outpatients for a further 4 mean days.
We conclude that selected out-hospital management of APL patients during consolidation therapy-induced aplasia is safe, well accepted and potentially cost-saving, as 76% of the neutropenia period was managed out of the hospital. This practice contributed in sparing these immunocompromised subjects the risk of developing infections due to highly pathogenic and antimicrobial-resistant nosocomial isolates.
The empiric therapy of febrile patients with once-a-day ceftriaxone plus amikacin was effective and made possible early discharge to continue the antibiotic therapy on an outpatient setting.
The availability of an EU specifically dedicated to outpatients with hematologic diseases was of crucial importance; the presence of a ward for short-term hospitalization proved to be of relevant use in the policy of hospital bed saving and of patient turnover of the whole Hematologic Center.
We are now planning the possibility of early discharge also in selected patients after induction chemotherapy or other intensive treatments in AML and other categories of patients, where we usually prolong hospitalization in view of the presumed high incidence of severe complications. A home care service available at our Center 13 might also have a crucial role in this setting.
